Showing session: reset
Clinical Trials Symposium 1: Clinical Trials of Agents Directed Towards PI3K and Metabolic Pathways
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Dejan Juric
Massachusetts General Hospital Cancer Center, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Lillian L. Siu
University Health Network Ontario Cancer Institute, Toronto, ON, Canada
- Free
- slides video
- audio + slides
- All slides included
A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies
Josep Tabernero
Vall d’Hebron Institue of Oncology, Barcelona, Spain
- Free
- slides video
- audio + slides
- All slides included
Discussant
Fabrice Andre
Institut Gustave Roussy, Villejuif, France
- Free
- slides video
- audio + slides
- All slides included
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
Funda Meric-Bernstam
UT M.D. Anderson Cancer Ctr., Houston, TX, United States
- Free
- audio + slides
- Some slides withheld
Discussant
Carlos L. Arteaga
Vanderbilt-Ingram Cancer Ctr., Nashville, TN, United States
- Permission not
granted for presentation
A phase II study of neoadjuvant metformin in prostatic carcinoma
Anthony M. Joshua
Princess Margaret Hospital, Toronto, ON, Canada
- Free
- audio + slides
- Some slides withheld
Discussant
Howard Scher
Memorial Sloan Kettering Cancer Center, NY, United States